Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 127 citing articles:

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Alan Menter, Bruce Strober, Daniel H. Kaplan, et al.
Journal of the American Academy of Dermatology (2019) Vol. 80, Iss. 4, pp. 1029-1072
Closed Access | Times Cited: 730
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, et al.
Arthritis Care & Research (2018) Vol. 71, Iss. 1, pp. 2-29
Open Access | Times Cited: 437
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, et al.
Arthritis & Rheumatology (2018) Vol. 71, Iss. 1, pp. 5-32
Open Access | Times Cited: 397
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, I. García‐Doval, et al.
Cochrane library (2017)
Open Access | Times Cited: 301
Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management
Ditte Marie Lindhardt Saunte, Ulrich Mrowietz, L. Puig, et al.
British Journal of Dermatology (2016) Vol. 177, Iss. 1, pp. 47-62
Closed Access | Times Cited: 241
Old and New Biological Therapies for Psoriasis
Kirsten Rønholt, Lars Iversen
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 11, pp. 2297-2297
Open Access | Times Cited: 218
Comparison of Biologics and Oral Treatments for Plaque Psoriasis
April W. Armstrong, L. Puig, Avani Joshi, et al.
JAMA Dermatology (2020) Vol. 156, Iss. 3, pp. 258-258
Open Access | Times Cited: 217
Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP
Hideki Fujita, Tadashi Terui, Koremasa Hayama, et al.
The Journal of Dermatology (2018) Vol. 45, Iss. 11, pp. 1235-1270
Open Access | Times Cited: 212
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, I. García‐Doval, et al.
Cochrane library (2020)
Open Access | Times Cited: 163
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, I. García‐Doval, et al.
Cochrane library (2021) Vol. 2021, Iss. 12
Open Access | Times Cited: 134
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, I. García‐Doval, et al.
Cochrane library (2022) Vol. 2022, Iss. 8
Open Access | Times Cited: 106
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, Robin Guelimi, et al.
Cochrane library (2023) Vol. 2023, Iss. 7
Open Access | Times Cited: 89
Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study
Kenshi Yamasaki, Hidemi Nakagawa, Yoshiaki Kubo, et al.
British Journal of Dermatology (2016) Vol. 176, Iss. 3, pp. 741-751
Open Access | Times Cited: 144
Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Fan Bai, Gang Gang Li, Qingmin Liu, et al.
Journal of Immunology Research (2019) Vol. 2019, pp. 1-25
Open Access | Times Cited: 141
Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response
L. Sawyer, K Malottki, Celia Sabry-Grant, et al.
PLoS ONE (2019) Vol. 14, Iss. 8, pp. e0220868-e0220868
Open Access | Times Cited: 137
A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis
Jawad Bilal, Adam Berlinberg, Sandipan Bhattacharjee, et al.
Journal of Dermatological Treatment (2018) Vol. 29, Iss. 6, pp. 569-578
Open Access | Times Cited: 114
Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups
Bridget Kaufman, Andrew Alexis
American Journal of Clinical Dermatology (2017) Vol. 19, Iss. 3, pp. 405-423
Closed Access | Times Cited: 109
A concise review on cancer treatment methods and delivery systems
Elham Bidram, Yasaman Esmaeili, Hadi Ranji‐Burachaloo, et al.
Journal of Drug Delivery Science and Technology (2019) Vol. 54, pp. 101350-101350
Closed Access | Times Cited: 107
Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis
Caleb Jeon, Sahil Sekhon, Di Yan, et al.
Human Vaccines & Immunotherapeutics (2017) Vol. 13, Iss. 10, pp. 2247-2259
Open Access | Times Cited: 103
The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases
S.P. Déo-Gracias Berry, Camille Dossou, Ali Kashif, et al.
International Immunopharmacology (2021) Vol. 102, pp. 108402-108402
Closed Access | Times Cited: 70
Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
April W. Armstrong, Ahmed M. Soliman, Keith A. Betts, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 3, pp. 885-905
Open Access | Times Cited: 62
Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence
Xiaoying Sun, Ziyang Cui, Qingyun Wang, et al.
Autoimmunity Reviews (2024) Vol. 23, Iss. 4, pp. 103530-103530
Closed Access | Times Cited: 10
Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation
Scott M. Whitlock, Clinton Enos, April W. Armstrong, et al.
Journal of the American Academy of Dermatology (2018) Vol. 78, Iss. 2, pp. 383-394
Closed Access | Times Cited: 81
Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trial
L. Puig, Mark Lebwohl, H. Bachelez, et al.
Journal of the American Academy of Dermatology (2019) Vol. 82, Iss. 2, pp. 352-359
Open Access | Times Cited: 70
Japanese guidance for use of biologics for psoriasis (the 2019 version)
Hidehisa Saeki, Tadashi Terui, Akimichi Morita, et al.
The Journal of Dermatology (2020) Vol. 47, Iss. 3, pp. 201-222
Open Access | Times Cited: 68
Page 1 - Next Page

Scroll to top